Abstract
The approval of CFTR modulators has opened the possibility of targeting the basic molecular defects underlying CF. Nevertheless, these molecules fail to completely rescue the activity of CFTR mutants, and patients with rare mutations are not eligible for these treatments. We previously conceived a cell-permeable mimetic peptide (PI3Kγ MP) that, by targeting PI3Kγ, induces cAMP elevation in CFTR proximity triggering PKA-mediate phosphorylation and CFTR opening.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.